Please login to the form below

Not currently logged in
Email:
Password:

IBS

This page shows the latest IBS news and features for those working in and with pharma, biotech and healthcare.

FDA awards another non-opioid pain drug breakthrough status

FDA awards another non-opioid pain drug breakthrough status

The Breakthrough Therapy designation is based on phase Ib placebo-controlled clinical trial in patients undergoing bunionectomy.

Latest news

More from news
Approximately 6 fully matching, plus 95 partially matching documents found.

Latest Intelligence

  • Erectile dysfunction, constipation, vaginal dryness and other laughing matters Erectile dysfunction, constipation, vaginal dryness and other laughing matters

    An Irritable Bowel Syndrome campaign tackled the challenge of IBS not being taken seriously by actually using humour. ... However, FiberOne poked fun at doctors and their scepticism of the legitimacy of IBS.

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    Data was presented from a Phase Ib study on Biogen’s aducanumab which showed statistically significant reductions in amyloid plaques in the brain compared with placebo among 31 early-stage ... Positive results from a phase Ib dose-escalation study were

  • Deal Watch January 2017 Deal Watch January 2017

    Assembly Biosciences. Allergan. Exclusive global licence . 2 pc candidates for ulcerative colitis (ABI-M201) and Crohn's disease plus 2 compounds for IBS.

  • Deal Watch January 2016 Deal Watch January 2016

    TEN-010, the lead, is a small molecule BET inhibitor that is in two phase Ib oncology studies. ... It is expected that $30m of payments will fall in 2016 relating to the phase Ib studies for SER 262 and a late stage study for SER 109 in CDI.

  • Pharma deals in February 2015 Pharma deals in February 2015

    diarrhoea (IBS-D) label be successful, this figure could rise to $2bn.

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics